Skip to main content

Main menu

  • HOME
  • CONTENT
    • Early Release
    • Featured
    • Current Issue
    • Issue Archive
    • Collections
    • Podcast
  • ALERTS
  • FOR AUTHORS
    • Information for Authors
    • Fees
    • Journal Clubs
    • eLetters
    • Submit
    • Special Collections
  • EDITORIAL BOARD
    • Editorial Board
    • ECR Advisory Board
    • Journal Staff
  • ABOUT
    • Overview
    • Advertise
    • For the Media
    • Rights and Permissions
    • Privacy Policy
    • Feedback
    • Accessibility
  • SUBSCRIBE

User menu

  • Log out
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Neuroscience
  • Log out
  • Log in
  • My Cart
Journal of Neuroscience

Advanced Search

Submit a Manuscript
  • HOME
  • CONTENT
    • Early Release
    • Featured
    • Current Issue
    • Issue Archive
    • Collections
    • Podcast
  • ALERTS
  • FOR AUTHORS
    • Information for Authors
    • Fees
    • Journal Clubs
    • eLetters
    • Submit
    • Special Collections
  • EDITORIAL BOARD
    • Editorial Board
    • ECR Advisory Board
    • Journal Staff
  • ABOUT
    • Overview
    • Advertise
    • For the Media
    • Rights and Permissions
    • Privacy Policy
    • Feedback
    • Accessibility
  • SUBSCRIBE
PreviousNext
Articles, Cellular/Molecular

LMTK3 Deficiency Causes Pronounced Locomotor Hyperactivity and Impairs Endocytic Trafficking

Takeshi Inoue, Naosuke Hoshina, Takanobu Nakazawa, Yuji Kiyama, Shizuka Kobayashi, Takaya Abe, Toshifumi Yamamoto, Toshiya Manabe and Tadashi Yamamoto
Journal of Neuroscience 23 April 2014, 34 (17) 5927-5937; https://doi.org/10.1523/JNEUROSCI.1621-13.2014
Takeshi Inoue
1Division of Oncology and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Naosuke Hoshina
1Division of Oncology and
5Cell Signal Unit, Okinawa Institute of Science and Technology, Onna-son, Okinawa 904-0495, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takanobu Nakazawa
1Division of Oncology and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuji Kiyama
2Division of Neuronal Network, Institute of Medical Science, University of Tokyo, Minato-ku, Tokyo 108-8639, Japan,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shizuka Kobayashi
2Division of Neuronal Network, Institute of Medical Science, University of Tokyo, Minato-ku, Tokyo 108-8639, Japan,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takaya Abe
3Laboratory for Animal Resources and Genetic Engineering, RIKEN Center for Developmental Biology, Kobe 650-0047, Japan,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Toshifumi Yamamoto
4Laboratory of Molecular Recognition, Graduate School of Arts and Sciences, Yokohama City University, Yokohama 236-0027, Japan, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Toshiya Manabe
2Division of Neuronal Network, Institute of Medical Science, University of Tokyo, Minato-ku, Tokyo 108-8639, Japan,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tadashi Yamamoto
1Division of Oncology and
5Cell Signal Unit, Okinawa Institute of Science and Technology, Onna-son, Okinawa 904-0495, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Expression profile of LMTK3 and generation of Lmtk3−/− mice. A, Schematic diagram of LMTK3, WT allele, a targeting vector, and a targeted allele after homologous recombination. Exons 1–3 encoding 1–120 aa of Lmtk3, which include N-terminal hydrophobic membrane targeting sequences (filled boxes) and a part of the Ser/Thr kinase domain (gray box) were replaced with lacZ and Neor. B, Tail genomic DNA [WT (+/+), heterozygous mutant (+/−), and homozygous mutant (−/−)] was digested with BglII and hybridized with a 5′ probe (indicated in A) for Southern blot analysis. C, Genotyping PCR of tail genomic DNA [WT (+/+), heterozygous mutant (+/−), and homozygous mutant (−/−)] using primers Pr1, Pr2, and Pr3 (indicated in A). D, Western blot analysis of WT (+/+), heterozygous (+/−), and homozygous (−/−) mutant mouse brain. Newborn brain lysates were probed with anti-LMTK3, anti-CYTH2, anti-β-galactosidase, and anti-α-tubulin antibodies. Asterisks indicate nonspecific signals. E–H, X-Gal staining of sagittal (E) and coronal (H) sections of the P1 Lmtk3+/− brain. F, G, High-magnification images of E to show strong expression in the cornu ammonis (CA) and dentate gyrus (DG) in the hippocampus (F) and prefrontal cortex (G). CTX, Cerebral cortex; HC, hippocampus; TH, thalamus. Scale bars: E, H, 0.5 mm.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Hyperactive and reduced anxiety-like behaviors in Lmtk3−/− mice. A–E, The open-field test. A, Increased horizontal activity of KO mice in a novel environment. WT, n = 10; Het, n = 10; KO, n = 9. F(2,26) = 97.61, p < 0.0001 for genotype, two-way repeated-measures ANOVA. WT versus KO: p < 0.0001. B, Typical examples of locomotor patterns of WT (top) and KO (bottom) mice during 15 min recordings. C, Increased vertical activity in KO mice in a novel environment. n = 7 for each genotype. F(1,12) = 5.34. *p = 0.0394 for WT versus KO in a novel environment, one-way ANOVA. D, KO mice spent less time immobile in both novel and familiar environments. WT, n = 10; Het, n = 10; KO, n = 9. F(1,17) = 119.59. ***p < 0.0001 for WT versus KO in a novel environment, F(1,17) = 44.21. ***p < 0.0001 for WT versus KO in a familiar environment, one-way ANOVA. E, Increased horizontal activity of KO mice in a familiar environment. WT, n = 10; KO, n = 9. F(1,17) = 29.72, p < 0.0001 for genotype, two-way repeated-measures ANOVA. F–I, The elevated plus maze test. F, The increased total distance traveled by mutants. WT, n = 13; KO, n = 11, F(1,22) = 117.8. ***p < 0.0001, one-way ANOVA. G, The increased total number of entries by mutants. WT, n = 13; KO, n = 11, F(1,22) = 170.1. ***p < 0.0001, one-way ANOVA. H, Increased time spent in the open arms by the mutants. WT, n = 13; KO, n = 11, F(1,22) = 70.3. ***p < 0.0001, one-way ANOVA. I, The increased number of entries into the open arms by mutants. WT, n = 13; KO, n = 11, F(1,22) = 19.3. ***p < 0.001, one-way ANOVA. J, The increased number of transitions between the light and dark compartments by mutants during the light/dark transition test. WT, n = 13; KO, n = 11, F(1,22) = 36.8. ***p < 0.0001, one-way ANOVA. K–M, Contextual and auditory fear conditioning tests. n = 15 for each genotype. K, Freezing responses on the conditioning day. A tone was presented for 10 s (solid line), and mice were given a footshock for 2 s (arrow). F(1,28) = 5.354, p = 0.0282 for genotype, two-way repeated-measures ANOVA. L, Freezing responses in the contextual fear conditioning test 24 h after conditioning. F(1,28) = 4.896, p = 0.0352 for genotype, two-way repeated-measures ANOVA. M, Freezing responses in the auditory fear conditioning test 48 h after conditioning. Three minutes after putting mice into a test chamber with novel contexts, the same tone was presented for 3 min (solid line). F(1,28) = 4.796, p = 0.037 for genotype, two-way repeated-measures ANOVA. Data are mean ± SEM.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Antidepression-like behaviors in Lmtk3−/− mice. A, B, The tail suspension test. A, The decreased percentage immobility time by mutants. WT, n = 12; KO, n = 11, F(1,21) = 30.81, p < 0.0001 for genotype, two-way repeated-measures ANOVA. B, A summary of the immobility time during the 6 min test. ***p < 0.001, one-way ANOVA. C, D, The forced swim test. C, The decreased percentage immobility time of mutants. WT, n = 13; KO, n = 11, F(1,22) = 22.33, p < 0.0001 for genotype, two-way repeated-measures ANOVA. D, A summary of the immobility time during the 10 min test. ***p < 0.001, one-way ANOVA. Data are mean ± SEM.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    Behavioral analyses of Lmtk3−/− mice by acoustic startle response and prepulse inhibition tests. A, Mean amplitudes of startle responses to acoustic stimuli. WT, n = 13; KO, n = 11, two-way ANOVA. F(4,110) = 1.853, p = 0.1239 for startle × genotype interaction; F(1,110) = 11.23, p = 0.0011 for genotype, followed by Bonferroni's test. **p = 0.0013 for 100 dB. B, Percentage prepulse inhibition. Prepulse sound at 75 or 80 dB was presented before the 120 dB startle stimuli. WT, n = 13; KO, n = 11, two-way ANOVA. F(1,44) = 0.5071, p = 0.4801 for genotype.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    Behavioral analyses of Lmtk3−/− mice by wire hang, tail flick, and accelerating rotarod tests. A, Wire hang test. Average latency to fall from the wire-mesh of two trials. n = 15 for each genotype. F(1,28) = 2.95, p = 0.0967, one-way ANOVA. B, Tail flick test. Average tail flick latency in response to heat stimulus over three trials. WT, n = 13; KO, n = 12, F(1,23) = 0.137, p = 0.704, one-way ANOVA. C, Accelerating rotarod test. Mice were trained for eight trials, four trials per day for two consecutive days. n = 15 for each genotype. F(1,28) = 0.130, p = 0.718, two-way repeated-measures ANOVA.

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    Effects of methylphenidate on locomotor activity. Horizontal activity was measured in the open-field test for 45 min after the injection of methylphenidate at the doses indicated (n = 12 [WT], n = 8 [KO] for vehicle (saline); n = 4 [WT], n = 10 [KO] for 0.05 mg/kg; n = 5 [WT], n = 4 [KO] for 0.3 mg/kg; n = 10 [WT], n = 6 [KO] for 3 mg/kg; n = 11 [WT], n = 8 [KO] for 10 mg/kg). F(4,68) = 1.895, p = 0.1214 for dose × genotype interaction; F(1,68) = 15.34, p = 0.0002 for genotype, two-way repeated-measures ANOVA, followed by Bonferroni's test. Data are mean ± SEM.

  • Figure 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 7.

    Subcellular distribution of LMTK3. A, Cultured cortical neurons (DIV7) were immunostained with anti-LMTK3 (red) and anti-GM130 (green) antibodies. Neuronal somas were outlined in the merged image for clarification of the cell shape. Scale bar, 10 μm. B, Cultured cortical neurons (DIV14) were labeled with Alexa546-Tf (red) and immunostained with anti-LMTK3 antibody (green). Arrowheads indicate the colocalization of LMTK3 with Tf-positive endosomal vesicles in the neurites. Scale bar, 2 μm. C, Cultured cortical neurons (DIV14) were immunostained with anti-LMTK3 (green), anti-VGLUT1 (red), and anti-PSD-95 (blue) antibodies. Arrowheads indicate the presence of LMTK3 in the close vicinity of VGLUT1/PSD-95-positive excitatory synapses. Scale bar, 2 μm. D, Cultured cortical neurons (DIV14) from Lmtk3+/+ (left) and Lmtk3−/− (right) embryos were transfected with EGFP expression plasmid. Two days after transfection, neurons were immunostained with anti-LMTK3 (red) and anti-GFP (green) antibodies. LMTK3 immunofluorescence was confirmed to be rarely detectable in Lmtk3−/− neurons. Neuronal morphology was assessed by GFP immunofluorescence. Spine densities were also quantified (n > 50 neurites in EGFP-expressing neurons of each genotype; p = 0.56). Scale bar, 10 μm. E, Biochemical fractionation of mouse brain lysate. An equal amount of protein from each fraction was probed with anti-LMTK3, anti-synaptophysin, and anti-PSD-95 antibodies. F, Biochemical preparation of the Golgi membrane fraction from mouse brain lysate by discontinuous sucrose density gradient. Equal amount proteins of each fraction were probed with anti-LMTK3, anti-GM130, anti-Rab8, and anti-EEA1 antibodies. G, Lysates from Lmtk3+/+ or Lmtk3−/− mouse brains were immunoprecipitated with an anti-LMTK3 antibody or a control rabbit IgG and analyzed using anti-α-adaptin antibody. Data are mean ± SEM; Student's t test.

  • Figure 8.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 8.

    Impaired NMDA receptor trafficking in Lmtk3−/− neurons. A, Biotinylation of surface proteins and endocytosis were performed as described in Materials and Methods. Total lysates, surface proteins, and endocytosed proteins of WT and KO neurons (DIV14) were analyzed by immunoblotting for GluN1, GluN2B, GluN2A, GluA1, TfR, GABAARβ2, and α-tubulin. Negligible α-tubulin immunoreactivity in “surface” and “endocytosed” lanes indicates successful biotin labeling and quenching of the surface proteins. B, Quantification of the immunoblot of A. n = 5 for GluN2B, GluN2A, and TfR; n = 3 for GluN1, GluA1, GluA2, and GABAARβ2. Data are mean ± SEM. *p < 0.05, Student's t test. ***p < 0.001, Student's t test. C, Cultured cortical neurons (DIV14) were immunostained with anti-LMTK3 (green) and anti-GluN1 (red) antibodies. Arrowheads indicate partial colocalization of LMTK3 with the NMDA receptors. Scale bar, 2 μm.

Tables

  • Figures
    • View popup
    Table 1.

    Monoamines and their metabolites in the striatuma

    Content or ratioLmtk3+/+Lmtk3−/−
    NE3.08 ± 0.364.01 ± 1.08
    DA666.52 ± 25.41667.30 ± 21.30
    DOPAC38.40 ± 1.0344.18 ± 1.99*
    HVA52.26 ± 2.2259.24 ± 2.48*
    3-MT27.86 ± 0.8532.14 ± 1.30*
    (DOPAC + HVA + 3-MT)/DA0.179 ± 0.0050.204 ± 0.006**
    5-HT22.99 ± 1.2123.03 ± 1.51
    5-HIAA14.53 ± 0.8915.12 ± 0.94
    5-HIAA/5-HT0.640 ± 0.0350.669 ± 0.035
    • ↵aThe values of neurochemical are shown as pmol/mg of protein (mean ± SEM; n = 14). The turnovers of metabolites are shown as the ratio of the neurochemicals. NE, Norepinephrine; DA, dopamine.

    • ↵*p < 0.05, compared with wild-type control.

    • ↵**p < 0.01, compared with wild-type control.

Back to top

In this issue

The Journal of Neuroscience: 34 (17)
Journal of Neuroscience
Vol. 34, Issue 17
23 Apr 2014
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Advertising (PDF)
  • Ed Board (PDF)
Email

Thank you for sharing this Journal of Neuroscience article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
LMTK3 Deficiency Causes Pronounced Locomotor Hyperactivity and Impairs Endocytic Trafficking
(Your Name) has forwarded a page to you from Journal of Neuroscience
(Your Name) thought you would be interested in this article in Journal of Neuroscience.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
View Full Page PDF
Citation Tools
LMTK3 Deficiency Causes Pronounced Locomotor Hyperactivity and Impairs Endocytic Trafficking
Takeshi Inoue, Naosuke Hoshina, Takanobu Nakazawa, Yuji Kiyama, Shizuka Kobayashi, Takaya Abe, Toshifumi Yamamoto, Toshiya Manabe, Tadashi Yamamoto
Journal of Neuroscience 23 April 2014, 34 (17) 5927-5937; DOI: 10.1523/JNEUROSCI.1621-13.2014

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Request Permissions
Share
LMTK3 Deficiency Causes Pronounced Locomotor Hyperactivity and Impairs Endocytic Trafficking
Takeshi Inoue, Naosuke Hoshina, Takanobu Nakazawa, Yuji Kiyama, Shizuka Kobayashi, Takaya Abe, Toshifumi Yamamoto, Toshiya Manabe, Tadashi Yamamoto
Journal of Neuroscience 23 April 2014, 34 (17) 5927-5937; DOI: 10.1523/JNEUROSCI.1621-13.2014
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Keywords

  • endocytosis
  • hyperactivity
  • LMTK
  • locomotor
  • membrane trafficking

Responses to this article

Respond to this article

Jump to comment:

No eLetters have been published for this article.

Related Articles

Cited By...

More in this TOC Section

Articles

  • Memory Retrieval Has a Dynamic Influence on the Maintenance Mechanisms That Are Sensitive to ζ-Inhibitory Peptide (ZIP)
  • Neurophysiological Evidence for a Cortical Contribution to the Wakefulness-Related Drive to Breathe Explaining Hypocapnia-Resistant Ventilation in Humans
  • Monomeric Alpha-Synuclein Exerts a Physiological Role on Brain ATP Synthase
Show more Articles

Cellular/Molecular

  • Atypical Cadherin FAT2 Is Required for Synaptic Integrity and Motor Behaviors
  • Sex Differences in Histamine Regulation of Striatal Dopamine
  • CXCL12 Engages Cortical Inhibitory Neurons to Enhance Dendritic Spine Plasticity and Structured Network Activity
Show more Cellular/Molecular
  • Home
  • Alerts
  • Follow SFN on BlueSky
  • Visit Society for Neuroscience on Facebook
  • Follow Society for Neuroscience on Twitter
  • Follow Society for Neuroscience on LinkedIn
  • Visit Society for Neuroscience on Youtube
  • Follow our RSS feeds

Content

  • Early Release
  • Current Issue
  • Issue Archive
  • Collections

Information

  • For Authors
  • For Advertisers
  • For the Media
  • For Subscribers

About

  • About the Journal
  • Editorial Board
  • Privacy Notice
  • Contact
  • Accessibility
(JNeurosci logo)
(SfN logo)

Copyright © 2025 by the Society for Neuroscience.
JNeurosci Online ISSN: 1529-2401

The ideas and opinions expressed in JNeurosci do not necessarily reflect those of SfN or the JNeurosci Editorial Board. Publication of an advertisement or other product mention in JNeurosci should not be construed as an endorsement of the manufacturer’s claims. SfN does not assume any responsibility for any injury and/or damage to persons or property arising from or related to any use of any material contained in JNeurosci.